Leerink Partnrs Has Strong Estimate for Illumina Q1 Earnings

Illumina, Inc. (NASDAQ:ILMN) – Equities researchers at Leerink Partnrs lifted their Q1 2025 earnings estimates for Illumina in a report released on Tuesday, January 7th. Leerink Partnrs analyst P. Souda now expects that the life sciences company will post earnings per share of $0.85 for the quarter, up from their previous forecast of $0.84. The consensus estimate for Illumina’s current full-year earnings is $4.11 per share.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, beating the consensus estimate of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The firm had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. During the same quarter in the prior year, the business posted $0.33 EPS. The business’s revenue for the quarter was down 3.5% compared to the same quarter last year.

Several other brokerages have also commented on ILMN. Morgan Stanley reaffirmed an “equal weight” rating and issued a $156.00 price objective on shares of Illumina in a research report on Tuesday, November 12th. Piper Sandler lowered their price objective on shares of Illumina from $195.00 to $185.00 and set an “overweight” rating for the company in a research note on Monday, November 11th. HSBC raised shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 price objective on the stock in a report on Thursday, October 17th. Leerink Partners raised their target price on Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. Finally, Canaccord Genuity Group boosted their price target on Illumina from $130.00 to $145.00 and gave the company a “hold” rating in a research note on Tuesday, November 5th. Eight equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $165.95.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $139.68 on Thursday. Illumina has a fifty-two week low of $100.08 and a fifty-two week high of $156.66. The company has a market cap of $22.15 billion, a PE ratio of -14.02 and a beta of 1.11. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. The business has a 50-day simple moving average of $141.37 and a two-hundred day simple moving average of $132.08.

Institutional Investors Weigh In On Illumina

A number of institutional investors have recently added to or reduced their stakes in the stock. Primecap Management Co. CA lifted its holdings in Illumina by 462.5% during the second quarter. Primecap Management Co. CA now owns 2,428,760 shares of the life sciences company’s stock valued at $253,514,000 after purchasing an additional 1,997,010 shares in the last quarter. Millennium Management LLC lifted its stake in Illumina by 305.0% in the 2nd quarter. Millennium Management LLC now owns 1,485,599 shares of the life sciences company’s stock valued at $155,067,000 after buying an additional 1,118,747 shares in the last quarter. Marshall Wace LLP acquired a new stake in Illumina in the 2nd quarter worth about $77,628,000. Massachusetts Financial Services Co. MA increased its stake in Illumina by 148.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,056,172 shares of the life sciences company’s stock worth $137,735,000 after buying an additional 631,294 shares in the last quarter. Finally, Janus Henderson Group PLC raised its holdings in shares of Illumina by 40.5% during the third quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock valued at $282,735,000 after acquiring an additional 625,245 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.